Enhanced COX-2 expression in breast cancer was first indicated by reports of elevated prostaglandin levels in breast carcinomas (Bennett et al, 1977), particularly in patients with metastatic disease (Rolland et al, 1980). This evidence concerns the gene PTGS2 and breast carcinoma.